Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas

Journal of Neuro-Oncology

Volumn 121, Issue 2, 2015, Pages 297-302

  Norden, Andrew D ^a,b,c   Schiff, David ^d   Ahluwalia, Manmeet S ^e   Lesser, Glenn J ^f   Nayak, Lakshmi ^a,b,c   Lee, Eudocia Q ^a,b,c   Rinne, Mikael L ^a,b,c   Muzikansky, Alona ^g   Dietrich, Jorg ^h   Purow, Benjamin ^d   Doherty, Lisa M ^b   LaFrankie, Debra C ^b   Pulverenti, Julee R ^b   Rifenburg, Jennifer A ^b   Ruland, Sandra F ^b   Smith, Katrina H ^b   Gaffey, Sarah C ^b   McCluskey, Christine ^b   Ligon, Keith L ^a,b,c   Reardon, David A ^b,c   Wen, Patrick Y ^a,b,c   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f WAKE FOREST BAPTIST HEALTH   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Anti angiogenic therapy; High grade glioma; Nintedanib

Indexed keywords

BEVACIZUMAB; CREATININE; NINTEDANIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; BODY WEIGHT DISORDER; BRAIN HEMORRHAGE; CLINICAL ARTICLE; COLON PERFORATION; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG TOLERABILITY; DUODENUM BLEEDING; DYSGEUSIA; DYSPEPSIA; DYSPHASIA; FATIGUE; FEMALE; GLIOBLASTOMA; GLIOMA; HOARSENESS; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOPHOSPHATEMIA; KARNOFSKY PERFORMANCE STATUS; LEUKOCYTE COUNT; LUNG EMBOLISM; LYMPHOCYTE COUNT; MACULOPAPULAR RASH; MALE; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUTROPHIL COUNT; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; THROMBOEMBOLISM; TUMOR RECURRENCE; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; CANCER GRADING; CLINICAL TRIAL; COHORT ANALYSIS; KAPLAN MEIER METHOD; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; GLIOMA; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; RECEPTOR PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME;

EID: 84925485508     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1631-y     Document Type: Article

References (25)

1. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740
2. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745
3. Piccioni DE, Selfridge J, Mody RR, Chowdhury R, Li S, Lalezari S, Wawrzynski J, Quan J, Zurayk M, Chou AP, Sanchez DE, Liau LM, Ellingson BM, Pope WB, Nghiemphu PL, Green RM, Wang HJ, Yong WH, Elashoff R, Cloughesy TF, Lai A (2014) Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro Oncol. doi:10.1093/neuonc/nou028
4. Quant EC, Norden AD, Drappatz J, Muzikansky A, Doherty L, Lafrankie D, Ciampa A, Kesari S, Wen PY (2009) Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 11:550–555
5. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95
6. Erber R, Thurnher A, Katsen A, Groth G, Kerger H, Hammes H, Menger M, Ullrich A, Vajkoczy P (2004) Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18:338–340
7. Guo P, Hu B, Gu W, Xu L, Wang D, Huang H, Cavenee W, Cheng S (2003) Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 162:1083–1093
8. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68:4774–4782. doi:10.1158/0008-5472.CAN-07-6307
9. Muhic A, Poulsen HS, Sorensen M, Grunnet K, Lassen U (2013) Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme. J Neurooncol 111:205–212. doi:10.1007/s11060-012-1009-y
10. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972. doi:10.1200/JCO.2009.26.3541
11. Simon R (1987) How large should a phase II trial of a new drug be? Cancer Treat Rep 71:1079–1085
12. Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, Degroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jurgensmeier JM, Jain RK, Sorensen AG, Xu J, Liu Q, van den Bent M (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31:3212–3218. doi:10.1200/JCO.2012.47.2464
13. Hutterer M, Nowosielski M, Haybaeck J, Embacher S, Stockhammer F, Gotwald T, Holzner B, Capper D, Preusser M, Marosi C, Oberndorfer S, Moik M, Buchroithner J, Seiz M, Tuettenberg J, Herrlinger U, Wick A, Vajkoczy P, Stockhammer G (2014) A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01–07). Neuro Oncol 16:92–102. doi:10.1093/neuonc/not161
14. Galanis E, Anderson SK, Lafky JM, Uhm JH, Giannini C, Kumar SK, Kimlinger TK, Northfelt DW, Flynn PJ, Jaeckle KA, Kaufmann TJ, Buckner JC (2013) Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clin Cancer Res 19:4816–4823. doi:10.1158/1078-0432.CCR-13-0708
15. Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, Marcello J, Herndon JE 2nd, McLendon RE, Janney D, Friedman AH, Bigner DD, Friedman HS (2011) Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 101:57–66. doi:10.1007/s11060-010-0217-6
16. Auguste P, Gursel DB, Lemiere S, Reimers D, Cuevas P, Carceller F, Di Santo JP, Bikfalvi A (2001) Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms. Cancer Res 61:1717–1726
17. Okamoto I, Kaneda H, Satoh T, Okamoto W, Miyazaki M, Morinaga R, Ueda S, Terashima M, Tsuya A, Sarashina A, Konishi K, Arao T, Nishio K, Kaiser R, Nakagawa K (2010) Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther 9:2825–2833. doi:10.1158/1535-7163.MCT-10-0379
18. Mross K, Stefanic M, Gmehling D, Frost A, Baas F, Unger C, Strecker R, Henning J, Gaschler-Markefski B, Stopfer P, de Rossi L, Kaiser R (2010) Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 16:311–319. doi:10.1158/1078-0432.CCR-09-0694
19. Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Gann CN, Barrueco J, Gaschler-Markefski B, Novello S, Group LU-LS (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15:143–155. doi:10.1016/S1470-2045(13)70586-2
20. Lampson LA (2011) Monoclonal antibodies in neuro-oncology: getting past the blood-brain barrier. mAbs 3:153–160
21. Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, Richel DJ, Leenders WP, van Furth WR (2009) Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 9:444. doi:10.1186/1471-2407-9-444
22. Veringa SJ, Biesmans D, van Vuurden DG, Jansen MH, Wedekind LE, Horsman I, Wesseling P, Vandertop WP, Noske DP, Kaspers GJ, Hulleman E (2013) In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma. PLoS ONE 8:e61512. doi:10.1371/journal.pone.0061512
23. Perry JR (2012) Thromboembolic disease in patients with high-grade glioma. Neuro Oncol 14(Suppl 4):iv73–80
24. Norden AD, Drappatz J, Ciampa AS, Doherty L, LaFrankie DC, Kesari S, Wen PY (2009) Colon perforation during antiangiogenic therapy for malignant glioma. Neuro Oncol 11:92–95. doi:10.1215/15228517-2008-071
25. Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY (2007) Medical management of brain tumor patients. Neurol Clin 25:1035–1071. doi:10.1016/j.ncl.2007.07.015